Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation

被引:103
作者
Brillanti, S [1 ]
Vivarelli, M
De Ruvo, N
Aden, AA
Camaggi, V
D'Errico, A
Furlini, G
Bellusci, R
Roda, E
Cavallari, A
机构
[1] Univ Bologna, Dept Internal Med & Gastroenterol, I-40138 Bologna, Italy
[2] Univ Bologna, Dept Surg & Transplantat, I-40138 Bologna, Italy
[3] Univ Bologna, Dept Hematol & Oncol, I-40138 Bologna, Italy
[4] Univ Bologna, Dept Clin & Expt Med, I-40138 Bologna, Italy
关键词
D O I
10.1053/jlts.2002.34640
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Chronic hepatitis C represents a major clinical problem after liver transplantation, but factors influencing the recurrent disease have not been well characterized. We analyzed the clinical records of all the patients transplanted for hepatitis C virus (HCV)-related liver disease in our Center between 1991 and 1997. Eighty consecutive HCV-positive (+) patients (60 men, ages 28 to 64) survived more than I month after transplantation and were followed for a median of 45 months. Diagnosis of recurrent chronic hepatitis C was made in 38 patients (47.5%), of whom 22 had moderate/severe chronic hepatitis. Decompensated cirrhosis occurred in six patients (7.5%). No difference in patient survival was found between patients with and without hepatitis C recurrence. No association was found between recurrent hepatitis C and presumed risk factors. The method of tapering off corticosteroids was significantly associated with both hepatitis C recurrence and the severity of hepatitis. In patients receiving a higher daily prednisone dose, 12 months after transplantation, the proportion of recurrent hepatitis C was 35.7% versus 66.6% (P = .02; odds ratio [OR], 3.6; 95% confidence interval (Cl): 1.25 to 10.36), and among patients receiving a higher daily prednisone dose, 6 months after transplantation, the proportion of moderate/severe chronic hepatitis C was 40% versus 89% (P = .03; OR: 0.08, 95% Cl: 0.008 to 0.84). Finally, prednisone dose at month six was significantly associated with disease-free survival of the liver graft. In conclusion, our results seem to indicate that in HCV-infected liver transplant recipients, a long-term treatment with corticosteroids, slowly tapered off over time, may prevent the more aggressive forms of recurrent liver disease.
引用
收藏
页码:884 / 888
页数:5
相关论文
共 12 条
[1]   HCV-related fibrosis progression following liver transplantation:: increase in recent years [J].
Berenguer, M ;
Ferrell, L ;
Watson, J ;
Prieto, M ;
Kim, M ;
Rayón, M ;
Córdoba, J ;
Herola, A ;
Ascher, N ;
Mir, J ;
Berenguer, J ;
Wright, TL .
JOURNAL OF HEPATOLOGY, 2000, 32 (04) :673-684
[2]   Long-term outcome of hepatitis C virus infection after liver transplantation [J].
Boker, KHW ;
Dalley, G ;
Bahr, MJ ;
Maschek, H ;
Tillmann, HL ;
Trautwein, C ;
Oldhaver, K ;
Bode, U ;
Pichlmayr, R ;
Manns, MP .
HEPATOLOGY, 1997, 25 (01) :203-210
[3]   Long-term outcome of hepatitis C infection after liver transplantation [J].
Cane, EJ ;
Portmann, BC ;
Naoumov, NV ;
Smith, HM ;
Underhill, JA ;
Donaldson, PT ;
Maertens, G ;
Williams, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (13) :815-820
[4]   Predictors of patient and graft survival following liver transplantation for hepatitis C [J].
Charlton, M ;
Seaberg, E ;
Wiesner, R ;
Everhart, J ;
Zetterman, R ;
Lake, J ;
Detre, K ;
Hoofnagle, J .
HEPATOLOGY, 1998, 28 (03) :823-830
[5]  
FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1002/hep.1840200506
[6]   European collaborative study on factors influencing outcome after liver transplantation for hepatitis C [J].
Féray, C ;
Caccamo, L ;
Alexander, GJM ;
Ducot, B ;
Gugenheim, J ;
Casanovas, T ;
Loinaz, C ;
Gigou, M ;
Burra, P ;
Barkholt, L ;
Esteban, R ;
Bizollon, T ;
Lerut, J ;
Minello-Franza, A ;
Bernard, PH ;
Nachbaur, G ;
Botta-Fridlund, D ;
Bismuth, H ;
Schalm, SW ;
Samuel, D .
GASTROENTEROLOGY, 1999, 117 (03) :619-625
[7]   SHORT-TERM PREDNISONE THERAPY AFFECTS AMINOTRANSFERASE ACTIVITY AND HEPATITIS-C VIRUS-RNA LEVELS IN CHRONIC HEPATITIS-C [J].
FONG, TL ;
VALINLUCK, B ;
GOVINDARAJAN, S ;
CHARBONEAU, F ;
ADKINS, RH ;
REDEKER, AG .
GASTROENTEROLOGY, 1994, 107 (01) :196-199
[8]  
MAGRIN S, 1994, HEPATOLOGY, V19, P273
[9]   Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation [J].
Nelson, DR ;
Soldevila-Pico, C ;
Reed, A ;
Abdelmalek, MF ;
Hemming, AW ;
Van der Werf, WJ ;
Howard, R ;
Davis, GL .
LIVER TRANSPLANTATION, 2001, 7 (12) :1064-1070
[10]   High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation:: Relationship with rejection episodes [J].
Prieto, M ;
Berenguer, M ;
Rayón, JM ;
Córdoba, J ;
Argüello, L ;
Carrasco, D ;
García-Herola, A ;
Olaso, V ;
De Juan, M ;
Gobernado, M ;
Mir, J ;
Berenguer, J .
HEPATOLOGY, 1999, 29 (01) :250-256